The Biotron Limited (ASX: BIT) share price soared by 30% today, after the biotechnology company released new data regarding the effectiveness of its lead antiviral drug BIT225, used for fighting HIV-1 infections.
The Biotron share price is on a tear this year, up more than 140% since January to 13 cents.
What did Biotron announce?
This morning, Biotron released data on its HIV-1 drug, BIT225. The data demonstrates how BIT225 enhances the immune response to HIV. Biotron commented that the drug is unique in that it not only inhibits the virus but also augments the immune responses against it.
"The latest results provide key information on how BIT225 directly modifies immune responses to HIV-1 infection. It helps explain the immune changes that we saw in the Phase 2 clinical trial and gives us even more confidence in our product," said Dr Michelle Miller, Biotron's managing director.
According to the report, specific cell markers that usually don't signal the immune system to attack the virus are instead returned to normal. Furthermore, the drug also increases functionality of the immune response by enabling T cells to more around the body and restore immune function.
These results, coupled with those from the Phase 2 clinical trial, further support the continued clinical study of the potential anti-viral and immunological benefits of BIT225 therapy in combination with standard anti-HIV drugs.
How Biotron is helping to combat COVID-19
It has been an exciting year for Biotron, which announced in March that its HIV-1 drug was able to restore immune function in HIV-1 infections. Furthermore, on 6 February Biotron announced plans to test its compounds against coronavirus, observing at the time it had over 30 compounds with good activity against a range of coronaviruses. Some of these compounds were stated to reduce the levels of coronavirus by 90–100% in infected cell cultures.
Biotron's expertise lies in the design and development of drugs that target virus-encoded proteins known as viroporins. The company's scientists were the first to identify and publish data showing that the E protein of the coronavirus is viroporin and a good target for antiviral drugs.
The Biotron share price is down on its 52-week high of almost 19 cents (reached in early February), but at its current price of 13 cents a share is up by 73.33% on this time last year.
